| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | Roscovitine | GDSC1000 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.023 | 0.9 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |